STOCK TITAN
  1. Home
  2. Sec-filings
  3. ELAN
  4. [Form 4] Elanco Animal Health Inc Insider Trading Activity

Elanco (NYSE: ELAN) director receives 4,678 deferred stock units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Elanco Animal Health director Deborah Turner Kochevar received an equity award of 4,678 shares of common stock on May 21, 2026. The Form 4 labels this as a grant or award acquisition at no cost per share, reported as a grant of deferred stock units for non-employee Board members. Following the award, she directly owns 94,392 shares of Elanco common stock. This is a routine director compensation grant rather than an open-market purchase.

Positive

  • None.

Negative

  • None.
Insider Kochevar Deborah Turner
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 4,678 $0.00 $0.00
Holdings After Transaction: Common Stock — 94,392 shares (Direct)
Footnotes (1)
  1. F1. Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.
Equity award size 4,678 shares Grant of common stock on May 21, 2026
Award price $0.00 per share Grant/award acquisition, compensation-related
Post-grant holdings 94,392 shares Shares of Elanco common stock directly owned after grant
Transaction date May 21, 2026 Date of equity award grant
deferred stock units financial
"Grant of deferred stock units as a pro-rated annual equity award"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
pro-rated annual equity award financial
"Grant of deferred stock units as a pro-rated annual equity award"
non-employee members of the Issuer's Board of Directors financial
"to each of the non-employee members of the Issuer's Board of Directors"
grant, award, or other acquisition financial
"transaction code description: Grant, award, or other acquisition"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Elanco (ELAN) director Deborah Turner Kochevar report in this Form 4?
Deborah Turner Kochevar reported receiving an equity award of 4,678 shares of Elanco common stock. The transaction is coded as a grant or award acquisition and reflects routine director compensation rather than an open-market stock purchase or sale.

How many Elanco (ELAN) shares does Deborah Turner Kochevar hold after this grant?
After the grant, Deborah Turner Kochevar directly holds 94,392 shares of Elanco common stock. This total includes the newly awarded 4,678 shares, which were granted as part of her compensation for serving on Elanco’s Board of Directors.

What type of equity award did Elanco (ELAN) grant to its director on May 21, 2026?
Elanco granted Deborah Turner Kochevar a pro-rated annual equity award of 4,678 deferred stock units, reported as common stock. The footnote describes this as a deferred stock unit grant to each non-employee member of Elanco’s Board of Directors for their board service.

Did Deborah Turner Kochevar buy Elanco (ELAN) shares on the open market?
No, the Form 4 shows a grant or award acquisition of 4,678 shares at a price of $0.00 per share. This indicates a compensation-related equity award, not an open-market purchase using personal funds on a stock exchange.

Why did Elanco (ELAN) grant 4,678 deferred stock units to its director?
The filing’s footnote explains the 4,678 units as a pro-rated annual equity award. It was granted to each non-employee member of Elanco’s Board of Directors as part of their director compensation, aligning them with shareholder interests through stock-based awards.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kochevar Deborah Turner
(Last)(First)(Middle)
C/O ELANCO ANIMAL HEALTH INCORPORATED
450 ELANCO CIRCLE
(Street)
INDIANAPOLIS INDIANA 46221
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/21/2026A4,678(1)A$094,392D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.
/s/ Amy C. Seidel, as Attorney-in-Fact for Deborah Turner Kochevar05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR